According to a post to ClinicalTrials.gov that was last updated on November 1, 2018, the Fuzzy Logic Automated Insulin Regulation, or FLAIR, study, which will investigate Medtronic’s (MDT) 670G hybrid closed loop system and advanced hybrid closed loop system in adolescents and young adults with type 1 diabetes, is estimated to start on March 30, 2019. According to an email from Craig-Hallum analyst Alexander Nowak, the trial was previously expected to start on September 1, 2018. Nowak has previously stated his belief that Tandem Diabetes (TNDM) is leading in terms of having the best automation and most discreet pump with Basal IQ, Control IQ launching within the next year and a 75% smaller pump than market leader Medtronic in the final stages of development. In afternoon trading, Tandem Diabetes shares are up $3.07, or 8.2%, to $40.68, while shares of another challenger in the space, Insulet (PODD), are up $2.47, or 2.8%, to $90.68.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.